Non-hepatic Cancer and Liver Transplantation:
Shifting the Paradigm. Dropping the Cancer Stigma.

HLTS seth CONSENSUS CONFERENCE virtual 2021
JANUARY 28-30, 2021

Consensus Conference Satellite Session

by Natera

Topic:

Advances in Molecular Residual Disease Assessment and Potential Applications in Liver Transplant Oncology

Introduction:

Identification of patients who achieved successful curative intent surgery continues to be a clinical challenge. Accurate identification of such patients could lead to treatment optimization with potential side-effect reduction, better resource allocation and improvement in quality of life and survival. Low levels of Circulating tumor DNA (ctDNA in the "sea" of normal DNA makes it challenging to detect molecular residual disease(MRD) in early-stage cancer. A tumor-informed approach where a sample of the patient's tumor tissue and a patient's blood sample is analyzed for germline mutations allows for increased sensitivity and specificity to find low levels of ctDNA in the background of cell free DNA. ctDNA has proven to be a clinically useful tool to determine residual molecular disease after surgery in early stage colorectal cancer and oligometastatic disease. Additionally treatment monitoring with reliable ctDNA marker can help stratify patients.

Objectives:

The objectives for this presentation will be to:

1. Provide an overview of Signatera's personalized ctDNA assay
2. Summarize clinical evidence in early stage and metastatic diseases, and
3. Discuss how this assay can change the paradigm of clinical care and clinical trial design in liver transplant oncology

Speaker: Angel Rodriguez, MD Medical Oncology Director Natera

Date: February 05, 2021

Time: 17:30 -17:50 CET

How to join on February 5!

Join via Zoom:
https://us02web.zoom.us/j/83563894622?pwd=OHpEbDl6UWxMdkk5b1pScWMzSlFYZz09
Meeting ID: 835 6389 4622
Passcode: 485042

Join via Phone:
Find your local phone number: https://us02web.zoom.us/u/kdI5ozVIcB
Meeting ID: 835 6389 4622
Passcode: 485042

ILTS acknowledges the generous support of Natera:

Download the Natera Booklet:

Natera's innovations in transplant oncology.